At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 14 enrolled
Drug / intervention
JNJ-64300535biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Open-label Study to Assess the Immunogenicity, Safety, and Reactogenicity of JNJ-64300535, a DNA Vaccine Administered by Electroporation-mediated Intramuscular Injection, in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating JNJ-64300535 for Healthy. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the cellular immunogenicity of 3 monthly electroporation-mediated intramuscular (IM) injections of JNJ-64300535 in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesBelgium
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartFeb 2021
Primary CompletionDec 2021
TodayJul 2026
First PostedFeb 3, 2021
Enrollment StartFeb 3, 2021
Primary CompletionDec 7, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.4 years ago
Interventions
JNJ-64300535biological
JNJ-64300535 injection will be administered intramuscularly.